{"id":"W2294562171","doi":"10.1200/jco.2013.31.15_suppl.tps7131","title":"A phase III, randomized, controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"ca_institutions":"Baker Hughes (Canada)","funders":"","keywords":"Idelalisib; Ofatumumab; Medicine; Internal medicine; Chronic lymphocytic leukemia; Bendamustine; Alemtuzumab; Fludarabine; Oncology; Ibrutinib; CD20; IGHV@; Gastroenterology; Leukemia; Immunology; Chemotherapy; Lymphoma; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.02568771,0.0002703251,0.00557296,0.0002693815,0.00008505047,0.0000281902,0.0002903233,0.0003226231,0.0001098681],"category_scores_gemma":[0.02668737,0.0001328688,0.0006021178,0.0003257221,0.0007606447,0.0001754696,0.00008369065,0.0008185147,0.000003254927],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.02151399,"about_ca_system_score_gemma":0.05445847,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001023037,"about_ca_topic_score_gemma":0.0002137034,"domain_scores_codex":[0.989578,0.003072881,0.005630534,0.000335954,0.0009279214,0.0004547279],"domain_scores_gemma":[0.957783,0.03631134,0.003654387,0.000388166,0.001557065,0.0003060718],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9245104,0.003405923,0.0004819777,0.0001326746,0.00208204,0.000118537,0.0008528499,0.0008266302,0.0002307025,0.00007306026,0.0002360699,0.06704912],"study_design_scores_gemma":[0.7466191,0.081435,0.00122218,0.000380589,0.001833631,0.0003059342,0.0004012739,0.1674765,0.00002510048,0.0001581633,0.00005020406,0.00009229791],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9839196,0.001424731,0.0003347879,0.0008538251,0.0001784006,0.01294142,0.000001375046,0.00001010898,0.0003357939],"genre_scores_gemma":[0.9975759,0.0006249851,0.0005458167,0.0002225433,0.0003177342,0.0004184127,0.00000430415,0.00003200085,0.0002583101],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1778913,"threshold_uncertainty_score":0.9822422,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08759778079866323,"score_gpt":0.4827884970728645,"score_spread":0.3951907162742012,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}